Pupillography as a sensitive, noninvasive biomarker in healthy volunteers: first-in-man study of BAY 63–9044, a new 5-HT1A-receptor agonist with dopamine agonistic properties

BAY 63-9044 is a new full 5-HT1A-agonist with functional dopamine agonist properties aimed for the treatment of Parkinson’s disease. This first-in-man study investigated the pharmacodynamics, safety and tolerability as well as the pharmacokinetics of BAY 63-9044 in a randomized, single-blind, placebo-controlled group-comparison dose escalation study. 45 healthy men received BAY 63-9044 as an oral solution in single doses of 0.25 mg, 0.5 mg,...